Pliant Therapeutics, Inc.
NASDAQ:PLRXBiotechnology
-$0.04 today
- Market cap
- $50.14M
- Beta
- 1.21
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.83
Volume 0.15M
Average 0.49M
PLRX Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Pliant Therapeutics, Inc.NASDAQ: PLRX
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue remains negative
Q1 FY2026 cost of revenue was $264K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $711K.
Context
- Cost of revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near $264K or moves back toward the trailing-twelve-month quarterly average of $177.75K.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 1.7M USD
- Year-over-year change
- —
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.7M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How PLRX compares with its peers on the latest reported figures
- PLRX's LTM Mar 2026 cost of revenue of $711K is the 3rd highest of the 10 companies compared; the peer median is $151K.
- Its year-over-year change of +14.3% is the 2nd highest of 7, against a peer median of -64.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.23M | -18.4% | +80.2% | 30.1% | |
| LTM Mar 2026 | $1.28M | -28.6% | -4.0% | 1.3% | |
| LTM Mar 2026 | $711K | +14.3% | — | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $666K | — | — | — |
| LTM Mar 2026 | $378K | +410.8% | +18.3% | 282.1% | |
| LTM Mar 2026 | $151K | — | — | — | |
| LTM Mar 2026 | $35K | — | — | 0.5% | |
| LTM Mar 2026 | $16.49K | -99.9% | -81.6% | 0.2% | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $5K | -100.0% | -71.8% | — |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| Peer median (excluding PLRX) | $151K | -64.2% | -4.0% | 1.3% | |
Competitors are the stored peer set for PLRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.57M | 9.69M | 1.58M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.7M |
| Gross Profit | 7.57M | 9.69M | 1.58M | 0 | (1.7M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 77.55M | 96.94M | 127.8M | 169.31M | 109.16M |
| Selling, General & Admin | 27.56M | 39.95M | 57.93M | 59.06M | 47.22M |
| Operating Expenses | 105.11M | 136.89M | 185.73M | 228.37M | 148.38M |
| Depreciation & Amortization | 1.54M | 3.68M | 1.84M | 2.13M | 1.7M |
| EBITDA | (95.73M) | (118.85M) | (158.23M) | (205.16M) | (145.09M) |
| EBITDA Margin | -1264.2% | -1227.1% | -10014.4% | — | — |
| Operating Income | (97.54M) | (127.2M) | (184.15M) | (228.37M) | (150.07M) |
| Operating Margin | -1288.1% | -1313.4% | -11654.7% | — | — |
| Interest Income | 272K | 4.67M | 24.08M | 21.09M | 0 |
| Interest Expense | 0 | 791K | 1.27M | 3.02M | 2.56M |
| Other Income / Expenses | 272K | 3.88M | 22.81M | 18.06M | 729K |
| Income Before Tax | (97.26M) | (123.32M) | (161.34M) | (210.3M) | (149.34M) |
| Pre-Tax Margin | -1284.5% | -1273.3% | -10211.1% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (97.26M) | (123.32M) | (161.34M) | (210.3M) | (149.34M) |
| Net Margin | -1284.5% | -1273.3% | -10211.1% | — | — |
| EPS (Basic) | (2.71) | (2.94) | (2.75) | (3.47) | (2.43) |
| EPS (Diluted) | (2.71) | (2.94) | (2.75) | (3.47) | (2.43) |
| Weighted Avg Shares | 35.85M | 42.02M | 58.72M | 60.54M | 61.37M |
| Weighted Avg Shares (Diluted) | 35.85M | 42.02M | 58.72M | 60.54M | 61.37M |
Pliant Therapeutics, Inc.
NASDAQ:PLRX
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.